Literature DB >> 19495851

Amiodarone for pediatric resuscitation: a word of caution.

Steven B Fishberger1, Robert L Hannan, Elizabeth M Welch, Anthony F Rossi.   

Abstract

Intravenous administration of amiodarone has recently been recommended for use during pediatric resuscitation of pediatric patients with ventricular fibrillation or pulseless ventricular tachycardia. We present two pediatric patients who received amiodarone for polymorphic ventricular tachycardia, although they were ultimately determined to have congenital long QT syndrome. Amiodarone is contraindicated in this setting and may have exacerbated the ventricular arrhythmia.

Entities:  

Mesh：

Substances：

Year:  2009        PMID： 19495851     DOI： 10.1007/s00246-009-9470-x

Source DB:  PubMed          Journal:  Pediatr Cardiol        ISSN： 0172-0643            Impact factor:   1.655


  10 in total

1.  Amiodarone-induced long QT and polymorphic ventricular tachycardia.

Authors:  V T Nkomo; W K Shen
Journal:  Am J Emerg Med       Date:  2001-05       Impact factor: 2.469

2.  2005 International Consensus on Cardiopulmonary Resuscitation and Emergency Cardiovascular Care Science with Treatment Recommendations. Part 6: Paediatric basic and advanced life support.

Authors: 
Journal:  Resuscitation       Date:  2005 Nov-Dec       Impact factor: 5.262

3.  2005 American Heart Association Guidelines for Cardiopulmonary Resuscitation and Emergency Cardiovascular Care.

Authors: 
Journal:  Circulation       Date:  2005-11-28       Impact factor: 29.690

4.  Preventing pediatric sudden cardiac death.

Authors:  Steven M Yabek
Journal:  Pediatrics       Date:  2007-02       Impact factor: 7.124

5.  Impact of early and standardized treatment with amiodarone on therapeutic success and outcome in pediatric patients with postoperative tachyarrhythmia.

Authors:  Nikolaus A Haas; Christoph K Camphausen
Journal:  J Thorac Cardiovasc Surg       Date:  2008-06-12       Impact factor: 5.209

6.  Congenital long QT syndrome: diagnosis and management in pediatric patients.

Authors:  Yaniv Bar-Cohen; Michael J Silka
Journal:  Curr Treat Options Cardiovasc Med       Date:  2006-09

7.  Amiodarone for post-operative junctional ectopic tachycardia.

Authors:  Kevin Plumpton; Robert Justo; Nikolaus Haas
Journal:  Cardiol Young       Date:  2005-02       Impact factor: 1.093

8.  Intravenous amiodarone for incessant tachyarrhythmias in children: a randomized, double-blind, antiarrhythmic drug trial.

Authors:  J Philip Saul; William A Scott; Stephen Brown; Pablo Marantz; Valeria Acevedo; Susan P Etheridge; James C Perry; John K Triedman; Susan W Burriss; Paul Cargo; Jay Graepel; Eeva-Kaarina Koskelo; Rebecca Wang
Journal:  Circulation       Date:  2005-11-29       Impact factor: 29.690

9.  Pediatric use of intravenous amiodarone: efficacy and safety in critically ill patients from a multicenter protocol.

Authors:  J C Perry; A L Fenrich; J E Hulse; J K Triedman; R A Friedman; J J Lamberti
Journal:  J Am Coll Cardiol       Date:  1996-04       Impact factor: 24.094

10.  Clinical efficacy and safety of intravenous Amiodarone in infants and children.

Authors:  F H Figa; R M Gow; R M Hamilton; R M Freedom
Journal:  Am J Cardiol       Date:  1994-09-15       Impact factor: 2.778
  10 in total
  2 in total

1.  Outcomes associated with amiodarone and lidocaine in the treatment of in-hospital pediatric cardiac arrest with pulseless ventricular tachycardia or ventricular fibrillation.

Authors:  Santiago O Valdes; Aaron J Donoghue; Derek B Hoyme; Rachel Hammond; Marc D Berg; Robert A Berg; Ricardo A Samson
Journal:  Resuscitation       Date:  2013-12-19       Impact factor: 5.262

2.  A pharmacokinetic model for amiodarone in infants developed from an opportunistic sampling trial and published literature data.

Authors:  Samantha H Dallefeld; Andrew M Atz; Ram Yogev; Janice E Sullivan; Amira Al-Uzri; Susan R Mendley; Matthew Laughon; Christoph P Hornik; Chiara Melloni; Barrie Harper; Andrew Lewandowski; Jeff Mitchell; Huali Wu; Thomas P Green; Michael Cohen-Wolkowiez
Journal:  J Pharmacokinet Pharmacodyn       Date:  2018-02-12       Impact factor: 2.410
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.